New Delhi News

Cystic Fibrosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Cystic Fibrosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 16
19:29 2023
Cystic Fibrosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Cystic Fibrosis Pipeline Insights
DelveInsight’s ‘Cystic Fibrosis Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Cystic Fibrosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystic Fibrosis pipeline domain.

DelveInsight’s Cystic Fibrosis Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Cystic Fibrosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystic Fibrosis pipeline domain.

Key Takeaways from the Cystic Fibrosis Pipeline Report

  • Over 80+ Cystic Fibrosis pipeline therapies are in various stages of development, and their anticipated acceptance in the Cystic Fibrosis market would significantly increase market revenue. 
  • Leading Cystic Fibrosis companies developing novel drug candidates to improve the Cystic Fibrosis treatment landscape include Algi Pharma, Verona Pharma, Translate Bio, Calithera Biosciences, Krystal Biotech, SpliSense, and others.
  • Promising Cystic Fibrosis pipeline therapies in various stages of development include OligoG, Ensifentrine, MRT5005, CB280, KB407, SPL84231, and others.

Cystic Fibrosis Overview

Cystic fibrosis is a disorder that damages your lungs, digestive tract and other organs. It’s an inherited disease caused by a defective gene that can be passed from generation to generation. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices.

Cystic Fibrosis Pipeline Analysis: Drug Profile

OligoG: Algi Pharma

OligoG is formulated as a dry powder for inhalation and is AlgiPharma’s lead drug candidate. It is an alginate oligosaccharide derived from seaweed, and is a new class of drug which is modulating mucus and normalizing mucus rheology. It is being developed to help people with cystic fibrosis clear mucus from their lungs. It is anticipated that OligoG may help to slow the progression of the disease. OligoG has been shown to disrupt the infectious biofilm often present in the lungs of individuals with CF. This biofilm disruption is believed to improve antibiotic effectiveness by increasing exposure of bacteria to antibiotics. It is in Phase 2 stage of development for the treatment of Cystic Fibrosis.

Discover more about the emerging Cystic Fibrosis drugs @ Cystic Fibrosis Treatment Drugs

Cystic Fibrosis Key Companies

  • Algi Pharma
  • Verona Pharma
  • Translate Bio
  • Calithera Biosciences
  • Krystal Biotech
  • SpliSense

Cystic Fibrosis Pipeline Therapies

  • OligoG
  • Ensifentrine
  • MRT5005
  • CB280
  • KB407
  • SPL84231

Cystic Fibrosis Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Cystic Fibrosis Pipeline Report 

  • Coverage: Global 
  • Key Cystic Fibrosis Companies: Algi Pharma, Verona Pharma, Translate Bio, Calithera Biosciences, Krystal Biotech, SpliSense, and others
  • Key Cystic Fibrosis Pipeline Therapies: OligoG, Ensifentrine, MRT5005, CB280, KB407, SPL84231, and others

Find out more about the Cystic Fibrosis treatment options in development @ Cystic Fibrosis Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report @ Cystic Fibrosis Clinical Trials

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles